Molecular Immunology Unit, Institute of Child Health, University College London, London, UK.
Mol Ther. 2010 Jul;18(7):1263-7. doi: 10.1038/mt.2010.76. Epub 2010 Apr 20.
Lentiviral vectors have remarkable cell entry and gene delivery properties that make them highly attractive for gene therapy. However, all integration-competent gene delivery systems have come under scrutiny for possible adverse insertional events. Circumventing the risk of insertional mutagenesis, integration-deficient human immunodeficiency virus (HIV)-1-derived vectors have been shown to support durable transcription of transgenes in certain nonmitotic cell lineages. In mitotic cell populations, such nonintegrated viral forms are lost during cell division and so have time-limited effects. Hybrid lentiviral vectors that harness the cell entry properties of HIV to facilitate carriage of alternative DNA modification systems into cells may allow durable genetic modification with more favorable integration profiles. Thus, systems, which have previously been plasmid-based such as those based on nuclease-enhanced homologous recombination (HR) and artificial transposons, have been incorporated into the viral genome to allow them to "hitch-hike" into cells that are difficult to transfect. Here, we review recent progress in the development of such hybrid lentiviral systems and consider potential applications of such vectors.
慢病毒载体具有显著的细胞进入和基因传递特性,使其非常适合基因治疗。然而,所有具有整合能力的基因传递系统都因可能的插入诱变而受到审查。已经证明,规避插入诱变风险的整合缺陷型人类免疫缺陷病毒 (HIV)-1 衍生载体能够在某些非有丝分裂细胞谱系中支持转基因的持久转录。在有丝分裂细胞群体中,这些非整合的病毒形式在细胞分裂过程中丢失,因此具有时间限制的作用。利用 HIV 的细胞进入特性来携带替代 DNA 修饰系统进入细胞的杂交慢病毒载体可能允许通过更有利的整合谱进行持久的基因修饰。因此,以前基于质粒的系统,如基于核酸酶增强的同源重组 (HR) 和人工转座子的系统,已被整合到病毒基因组中,以允许它们“搭便车”进入难以转染的细胞。在这里,我们回顾了此类杂交慢病毒系统的最新进展,并考虑了此类载体的潜在应用。